Buléon, Clément http://orcid.org/0000-0003-4550-3827
Parienti, Jean-Jacques
Morilland-Lecoq, Elodie
Halbout, Laurent
Cesaréo, Eric
Dubien, Pierre-Yves
Jardel, Benoit
Boyer, Christophe
Husson, Kévin
Andriamirado, Florian
Benet, Xavier
Morel-Marechal, Emmanuel
Aubrion, Antoine
Muntean, Catalin
Dupire, Erwan
Roupie, Eric
Hubert, Hervé
Vilhelm, Christian
Gueugniaud, Pierre-Yves
,
Funding for this research was provided by:
Direction Générale de l’offre de Soins
Article History
Received: 16 April 2020
Accepted: 19 June 2020
First Online: 8 July 2020
Ethics approval and consent to participate
: The South-West and Over-Sea 4 Ethics Committee (IRB No.: IORG0009855, Chairperson Claire Bahans) approved the study on November 9, 2018, under the registration number CPP18-071a/2018-2000-55, amended on August 29, 2019, under reference AM2019-171/02/CPP18-071. Because of the cardiac arrest status of the patients in the trial and the need to proceed with the intervention in a timely manner, according to the French Public Health law on clinical research in emergency conditions (art. L1122-1-2), prior informed consent was waived. The patient’s consent (InternalRef removed) will be asked and written when and if possible in the ICU by the medical staff in charge of the patient. If not possible (death of the patient), the data gathered will be used. Any change in the study design will be subject to a protocol amendment reviewed and submitted to the ethics committee for approval and then updated in the Clinical Trial registration.Additional biological samples will be obtained to be stored for use in future studies of the pathobiology of CA for patients who will be hospitalized in the ICU. Material consent will be obtained to specifically address the collection of these blood samples. Signed consent must be obtained from every patient in the ancillary study when and if possible in the ICU by the medical staff in charge.
: Not applicable.
: The authors declare that they have no competing interests.